SELLAS Life Sciences Group heads into its August 12 earnings report as one of the most heavily shorted small-cap biotechs in the market, with the lending pool telling a story of sustained bear conviction — even as borrow costs have fallen sharply from their peak.
Short sellers have not blinked. Short interest holds at 37.3% of the free float — roughly 53 million shares — and has declined only modestly from a July high above 67 million shares. That partial covering coincided with the stock falling 13% over the past month to $11.05, suggesting shorts took some profit into weakness rather than closing positions on conviction. The ORTEX short score confirms the pressure: it reads 81.8 on a scale to 100, placing SLS in the 2nd percentile of all stocks by short score rank and the 5th percentile by availability rank. Days to cover run nearly eight sessions, meaning a forced covering event would not be trivial to execute.
The borrow market has loosened from extreme levels, but it remains tight. Availability has climbed to roughly 16% — meaning only about one share is available for every six already borrowed. That is meaningfully better than early August, when availability briefly fell to near zero as every share in the lending pool was lent out. Borrowing costs peaked above 190% annualised in early July and have since eased to around 16%, a sharp move that reflects the partial short covering seen since mid-July. The direction of travel matters: availability is rising and costs are falling, which removes some of the squeeze pressure that built through June and July.
Options traders are not particularly defensive into the print. The put/call ratio of 0.41 is almost exactly in line with its 20-day average, with a z-score near zero — a neutral read. That sits well below the 52-week high of 0.46 reached in mid-July. The contrast is notable: while short sellers maintain a heavy structural position, the options market shows no incremental hedging demand ahead of earnings. The setup is one of entrenched bearish positioning rather than fresh defensive activity.
The fundamental debate is narrow but intense. SELLAS is a pre-revenue clinical-stage oncology company — negative earnings, negative return on assets, and a Piotroski F-score of just 2 — so the bull case rests entirely on pipeline advancement for its lead cancer immunotherapy program. The most recent analyst note of consequence came from Maxim Group in March 2026, which raised its target to $10 from $7 while maintaining a Buy. At the current price of $11.05, the stock has already traded through that target. The mean analyst price target of $27.50 implies substantial upside, but the coverage base is thin and the most recent data is over a month old, so that figure should be treated with caution. Bears, meanwhile, can point to a 37% short interest position held by investors with months of conviction and a stock that has already given back 13% of its recent gains.
Institutional ownership has shifted in ways worth noting. BlackRock added nearly 2.9 million shares as of July 31, bringing its stake to 7.7% of shares outstanding. State Street added 4.6 million shares in the same period. Those are material additions from passive-leaning institutions, likely reflecting index rebalancing following the stock's sharp year-to-date rally rather than active conviction — but they add supply-side support to the float nonetheless.
The earnings print will test whether any clinical or operational update is sufficient to justify the stock's current price against a short base that remains among the largest in small-cap biotech.
See the live data behind this article on ORTEX.
Open SLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
